Adult Stem Cells Show Potential for Treating GVHD

May 9th 2022

The administration of adult stem cells increased survival in patients with both acute and chronic graft-versus-host disease in a compassionate use program.

Biosimilars Made a Significant Dent on 2021 Drug Spending

May 9th 2022

Although spending on prescription drugs marched higher in 2021, the spending might have been significantly higher were it not for the savings from biosimilars, which appear to be gaining traction, according to a new report.

Dupixent Safe, Effective Up to Four Years in Adults With Moderate-to-Severe Atopic Dermatitis

May 9th 2022

Safe and effective long-term treatment is important for stable disease control in atopic dermatitis.

Fixing the Coverage Gap After Incarceration

May 8th 2022

Healthcare insurance in the U.S. can be spotty, even with expansion of coverage under the Affordable Care Act. One of the remaining problem areas is coverage for people who are leaving prison or jail.

FDA Updates for the Week of May 2, 2022

May 7th 2022

The FDA has approved a rare disease therapy and an additional indication for Enhertu, and grants priority review for Imfinzi in biliary tract cancer. Regulators have issued complete response letters for three therapies. The agency also has scheduled an advisory committee for Nuplazid in Alzheimer’s psychosis.